Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis' Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria

pharmafileSeptember 19, 2017

Tag: Novartis , Urticaria

PharmaSources Customer Service